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Abstract: Glioblastoma multiforme (GB) is the most malignant primary brain tumor in humans, 
with an overall survival of approximatively 15 months. The molecular heterogeneity of GB, as well 
as its rapid progression, invasiveness and the occurrence of drug-resistant cancer stem cells, limits 
the efficacy of the current treatments. In order to develop an innovative therapeutic strategy, it is 
mandatory to identify and characterize new molecular players responsible for the GB malignant 
phenotype. In this study, the RNA-binding ubiquitin ligase MEX3A was selected from a gene 
expression analysis performed on publicly available datasets, to assess its biological and still-
unknown activity in GB tumorigenesis. We find that MEX3A is strongly up-regulated in GB 
specimens, and this correlates with very low protein levels of RIG-I, a tumor suppressor involved 
in differentiation, apoptosis and innate immune response. We demonstrate that MEX3A binds RIG-
I and induces its ubiquitylation and proteasome-dependent degradation. Further, the genetic 
depletion of MEX3A leads to an increase of RIG-I protein levels and results in the suppression of 
GB cell growth. Our findings unveil a novel molecular mechanism involved in GB tumorigenesis 
and suggest MEX3A and RIG-I as promising therapeutic targets in GB. 
Keywords: glioblastoma multiforme (GB); ubiquitylation; E3-ligase; MEX3A; RIG-I 
 
1. Introduction 
Glioblastoma multiforme (GB) is the most frequent and malignant primary tumor of the central 
nervous system [1], with a median overall survival of about 15 months [2–4]. GB is particularly 
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difficult to treat, given its intense vascularization, rapid progression and high resistance to standard 
treatments [2]. The current therapeutic protocol for GB patients consists of surgical resection of tumor 
mass and subsequent concomitant radiotherapy and chemotherapy. However, these approaches 
show very limited effectiveness, resulting in a high rate of relapse and subsequent deterioration of 
the patient’s neurological and physiological status [2,5]. 
In the recent years, several genetic and epigenetic aberrations in molecular pathways (i.e., WNT 
and Hedgehog signaling) [6–9] have been associated with GB onset and progression, representing 
potential therapeutic targets and biomarkers for early prognosis [2,3,5]. Hence, the identification and 
characterization of new molecular players involved in GB tumorigenesis is essential for developing 
more effective and innovative therapies against this aggressive malignancy. 
Ubiquitylation is a post-translational modification that controls a wide range of cellular 
functions (i.e., protein degradation, endocytosis and trafficking) and the most important 
physiological processes [10,11]. Ubiquitylation is mediated by an enzymatic cascade, in which the E3-
ubiquitin ligases are the main players, responsible for the recognition of specific substrates and the 
final transferring of ubiquitin moieties onto target proteins. 
Deregulation or mutations of E3-ubiquitin ligases have been associated with several human 
tumors; for this reason, they are considered to be promising targets for novel anticancer therapies 
[12–14]. At present, very little information is available about the role of E3 ligases and ubiquitylation 
processes in GB development and progression [15–17]. 
In this regard, we evaluated the expression levels of catalytic E3-ubiquitin ligase complex 
components [18] and F-box proteins of the SCF E3 ligase families in GB. From a preliminary gene 
expression analysis using publicly available datasets, we found a marked overexpression of MEX3A, 
and we investigated its potential involvement in GB biology.  
MEX3A belongs to an evolutionary conserved RNA-binding ubiquitin ligase protein family 
composed of four members (MEX3A-D). These proteins are the homologs of Caenorhabditis elegans 
MEX3, a translational repressor involved in germline totipotency and in the specification of posterior 
blastomere identity during embryogenesis [19]. Human MEX3 proteins consist of two N-terminal K 
homology (KH) domains, which provide RNA-binding ability, and a C-terminal RING finger module 
that confers ubiquitin E3-ligase activity [19]. MEX3 proteins play pivotal role in self-renewal and 
differentiation processes, with implications regarding stemness and carcinogenesis [20–25]. In 
particular, alterations of MEX3A activity have been described in gastric, colorectal and bladder 
cancers, although its mechanism of action and its potential substrates remain still elusive [21–24,26]. 
To date, only the RING finger domain of human MEX3C has been functionally and structurally 
characterized, and Retinoic acid-inducible gene I (RIG-I) is the unique substrate described for this E3 
ligase [27]. Interestingly, the ubiquitylation of RIG-I mediated by MEX3C leads to RIG-I activation, 
without interfering with its degradation and protein stability [28]. 
RIG-I is a critical cytosolic pattern recognition receptor (PRR) that acts as RNA sensor to activate 
innate antiviral immunity and interferon (IFN) production [29]. However, recent findings 
highlighted the role of this protein in other cellular functions, as well as therapy resistance and 
expansion of cancer cells [30,31]. Furthermore, RIG-I works as a tumor suppressor in several tumor 
types, including GB [32,33]. 
In this study, we observed that MEX3A is up-regulated in GB and correlates with low RIG-I 
protein levels. We demonstrated that MEX3A interacts with RIG-I and impairs its protein stability by 
inducing its ubiquitylation and proteasome-dependent degradation. Interestingly, the genetic 
depletion of MEX3A results in the impairment of GB cell proliferation, providing new insights on GB 
tumor biology and identification of potential and innovative therapeutic approaches. 
2. Results 
2.1. MEX3A Expression is Up-Regulated in GB 
To examine the expression of catalytic E3 ubiquitin ligases [18] and F-box proteins in GB, we 
first analyzed their expression in Gene Expression Profiling Interactive Analysis (GEPIA) 
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(http://gepia.cancer-pku.cn/) (Figure 1A). We focused our attention on E3 ligases significantly up-
regulated and whose molecular functions in GB tumorigenesis have not yet been described. Among 
them, we found the mRNA expression levels of the RNA-binding ubiquitin E3-ligase MEX3A 
strongly up-regulated in GB specimens compared to normal brain tissues (Figure 1B and Table S1). 
This evidence was further confirmed in smaller datasets available at the R2 Genomics and 
Visualization Platform (http://r2.amc.nl) (Figure S1A). These data were then validated in 27 GB 
specimens (Table 1) by assessing the mRNA expression levels of MEX3A. As shown in Figure 2A, we 
confirmed that the expression of MEX3A was significantly higher in GB samples compared to 
paratumor tissues, used as control. 
 
 
Figure 1. Gene expression profile of E3-ligases and F-box proteins in GB. (A) Heatmap shows a Z-
score transformed gene expression values of catalytic E3-ligases and F-box proteins between normal 
brain tissues (NBTs) and GB specimens. Average linkage was used as hierarchical clustering method 
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with Euclidean distance measurement. Color scale bar indicates the intensity associated with 
normalized expression values. (B) Gene expression of MEX3A in GB compared to NBTs. * p < 0.05. 
All the data were retrieved from Gene Expression Profiling Interactive Analysis (GEPIA) 
(http://gepia.cancer-pku.cn/). 
 
Figure 2. MEX3A expression is up-regulated in GB specimens. (A–C) Quantitative real-time PCR 
(qRT-PCR) analysis of MEX3A, RNF122 and MEX3C gene expression in GB samples described in 
Table 1 compared to corresponding paratumor tissues. Data are normalized to endogenous GAPDH 
and HPRT controls. Mean ± SD; * p < 0.05; ** p < 0.01; *** p < 0.001 calculated with two-sided Student’s 
t-test. 
Table 1. Characteristics of 27 high-grade GB specimens. 
Characteristics Number of Patients (27) 
Age years  (%) 
<60 44.45 
≥60 55.55 
Sex  
Male 51.85 
Female 48.15 
IDH1 status  
Wild Type 77.77 
Mutant 7.4 
n.d. 14.83 
EGFR expression  
Not expressed 22.22 
Expressed 22.22 
Highly expressed 25.92 
n.d. 39.63 
p53 expression  
Not expressed 37.03 
Very Low Expressed 7.4 
Expressed 40.74 
n.d. * 14.83 
* n.d. not determined. 
2.2. MEX3A Up-Regulation Correlates with Low Protein Levels of RIG-I in GB 
At present, ubiquitylation substrates of MEX3A have not been identified. We first hypothesized 
that this E3-ubiquitin ligase could be involved in the regulation of RIG-I, a tumor suppressor that 
controls differentiation, apoptosis and tumorigenesis processes. This idea was supported by the 
evidence that RIG-I stability and activity is modulated by the E3-ligases RNF122 [34] and MEX3C 
(the MEX3A paralogue) [20], whose mRNA expression levels were found to be up-regulated in GB 
(Supplementary Figure S1B,C and Figure 2C) [20,28,34]. 
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Given the double function of MEX3A as RNA-binding protein and E3-ubiquitin ligase [19], we 
first analyzed the mRNA expression levels of RIG-I in GB. As shown in Figure 3A, we did not observe 
significant modulation of mRNA levels of RIG-I in GB specimens compared to noncancerous brain 
tissues. 
Conversely, an opposite trend of MEX3A and RIG-I protein levels was observed in GB samples. 
Indeed, RIG-I protein levels were strongly decreased in GB tissues, in which high MEX3A protein 
levels were found; an inverse trend of the protein expression was observed in the corresponding 
paratumor samples (Figure 3B,C). These results were further confirmed by assessing the expression 
of RIG-I and MEX3A by immunohistochemistry staining of paratumor and GB tissue sections (Figure 
3D,E). Accordingly, we observed a remarkable protein expression of MEX3A in three GB cell lines 
(U87, A-172 and T98G) compared to normal brain tissue (NBT) and normal brain cells (NBC) used as 
a control, which correlated with low RIG-I protein levels (Figure 3F,G). 
 
Figure 3. MEX3A up-regulation is associated with low RIG-I protein level in GB. (A) qRT-PCR gene 
expression analysis of RIG-I in GB specimens shown in Table 1. Data were normalized to endogenous 
GAPDH and HPRT controls. (B) Representative immunoblotting analysis of MEX3A and RIG-I 
proteins levels in three GB and paratumor paired samples. (C) Densitometric analysis of actin-
normalized of MEX3A and RIG-I protein levels shown in (B). (D) H&E and immunohistochemical 
staining of MEX3A and RIG-I of the GB and paratumor samples analyzed in (B). Scale bar 100 μm. 
(E) Quantification of immunohistochemical staining shown in (D). (F) MEX3A and RIG-I steady state 
in normal brain tissue (NBT) and normal brain cells (NBC) compared to GB cell lines. (G) 
Densitometric analysis of actin-normalized protein levels assayed in (F) represents the mean of three 
independent experiments. Mean ± SD; * p < 0.05; ** p < 0.01 determined with two-sided Student’s t-
test. 
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Overall these data suggested MEX3A as a potential regulator of RIG-I protein. 
2.3. MEX3A Impairs RIG-I Protein Stability 
To investigate if MEX3A is involved in the regulation of RIG-I, we evaluated the effect of its 
ectopic expression on RIG-I protein levels. As shown in Figure 4A,B, increasing amounts of MEX3A 
lead to a robust reduction of RIG-I protein levels. Moreover, we compared the effects of MEX3A 
versus MEX3C and RNF122, and both are found to be up-regulated in GB (Figure S1B,C and Figure 
2B,C) and are known to mediate RIG-I stabilization and degradation, respectively [28,34]. 
 
Figure 4. MEX3A expression affects RIG-I protein stability. (A,B) Representative immunoblotting (A) 
and densitometric analysis (B) of GFP-RIG-I protein level in HEK293T cells transfected with 
increasing amounts of Myc-tagged MEX3A, MEX3C and RNF122, in a (1:1) and (1:0.5) ratio, compared 
to the amount of the transfected GFP-RIG-I. (C) HEK293T cells were transfected with equal quantities 
of GFP-RIG-I and Myc-tagged MEX3A and MEX3C, alone or in combination. The levels of the 
indicated protein were assessed by immunoblot analysis. (D) Densitometric analysis of GFP-RIG-I 
protein levels shown in (C) and normalized on actin levels. (E) HEK293T cells were co-transfected 
with GFP-RIG-I, an empty vector as control or Myc-MEX3A, in a ratio (1:0.5). Twelve hours after 
transfection, GFP-RIG-I half-life was assayed, following treatment with CHX (100 μg/mL), at the 
indicated time. (F) Densitometric analysis of RIG-I protein levels shown in (E) and normalized on 
actin levels. (G) Protein expression levels of endogenous MEX3A and RIG-I in A-172 and T98G GB 
cell lines transduced with lentiviral vectors encoding either control shRNA (shCTR) or MEX3A 
shRNAs (shMEX3A#1 and shMEX3A#2). (H) Densitometric analysis of RIG-I and MEX3A protein 
levels shown in (G) and normalized on actin levels. (I) Half-life of endogenous RIG-I in T98G cells 
infected with lentiviral particles encoding shCTR or shMEX3A#2. Cells were treated with CHX (50 
μg/mL) at the indicated time points. (J) Densitometric analysis of the RIG-I protein levels shown in 
(I). All the densitometric analysis represent the mean of protein levels of three independent 
experiments. Mean ± SD; * p < 0.05; ** p < 0.01; *** p < 0.001 calculated with two-sided Student’s t-test. 
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Interestingly, MEX3A showed a robust effect on the reduction of RIG-I protein expression 
(Figure 4A,B), without affecting its mRNA levels (Figure S2A), and it was able to counteract the effect 
of MEX3C on the stability of RIG-I when the two E3-ligases were co-expressed (Figure 4C,D). 
We further confirmed the effect of MEX3A on RIG-I protein stability by cycloheximide (CHX) 
assay. Half-life of RIG-I was significantly decreased in presence of ectopic expression of MEX3A, 
suggesting the role of this E3 ligase in the degradation of RIG-I (Figure 4E,F). Accordingly, we 
observed an increase of endogenous RIG-I protein levels, following the genetic depletion of MEX3A 
in A-172 and T98G GB cell lines (Figure 4G,H). A significant increase of the endogenous RIG-I half-
life was also observed in T98G cells genetically silenced for MEX3A after CHX treatment (Figure 4I,J). 
In all these conditions, no modulation of RIG-I mRNA levels was observed (Figure S2B–D). Together, 
these findings indicated that MEX3A regulates RIG-I protein stability. 
2.4. MEX3A Binds and Ubiquitylates RIG-I 
To elucidate the molecular mechanisms through which MEX3A controls RIG-I stability, we 
tested the ability of MEX3A to interact with RIG-I. To verify this hypothesis, we carried out reciprocal 
co-immunoprecipitation (Co-IP) experiments in HEK293T cells transfected with Myc-MEX3A and 
GFP-RIG-I expression plasmids. The immunoblot analysis revealed that MEX3A binds RIG-I (Figure 
5A,B). The interaction between endogenous MEX3A and RIG-I was also confirmed in A-172 and T98G 
GB cell lines (Figure 5C,D) and in GB tissues (Figure 5E). 
 
 
Figure 5. MEX3A interacts with RIG-I mediating its ubiquitylation. (A,B) HEK293T cells were co-
transfected with GFP-RIG-I and Myc-MEX3A in a (1:0.5) ratio, respectively. Interaction between RIG-
I and MEX3A was detected by immunoprecipitation, followed by immunoblot analysis with the 
indicated antibodies. (C,D) Interaction between endogenous RIG-I and MEX3A was assessed by 
immunoprecipitation and immunoblotting in A-172 (C) and T98G (D) GB cell lines. (E) Binding 
between endogenous RIG-I and MEX3A was assessed by co-immunoprecipitation assay in GB clinical 
sample. (F) GFP-RIG-I was immunoprecipitated from HEK293T expressing the indicated proteins and 
treated with MG132 (50 μM) or control for 4 h, followed by immunoblotting with an anti-HA antibody 
to detect conjugated HA-Ub. Ubiquitylation blot was re-probed with a GFP antibody, to detect the 
immunoprecipitated level of RIG-I. Bottom GFP-RIG-I and Myc-MEX3A protein levels in total cell 
lysate. (G) Densitometric analysis of the levels of the indicated protein shown in (F) represents the 
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mean of three independent experiments. Mean ± SD; ** p < 0.01 calculated using two-tailed Student’s 
t-test. 
Next, we verified whether MEX3A controls RIG-I protein levels by inducing its ubiquitin-
dependent degradation. To this aim, we performed an in vivo ubiquitylation assay upon ectopic 
expression of MEX3A. Increasing amounts of MEX3A promoted the poly-ubiquitylation of RIG-I and 
its subsequent degradation by the proteasome, as indicated by the accumulation of RIG-I 
ubiquitylated forms and its protein levels in cells treated with the proteasome-inhibitor MG132 
(Figure 5F,G). 
Overall, these results indicated that MEX3A interacts with RIG-I and mediates its ubiquitylation, 
thereby inducing RIG-I proteasome-dependent degradation. 
2.5. MEX3A Affects GB Cell Proliferation 
To investigate the biological relevance of MEX3A function in GB, we analyzed the effect of its 
genetic depletion on the proliferation ability of two GB cell lines. We observed a decrease in cell 
growth over time and a significant reduction of BrdU uptake in A-172 cells silenced for MEX3A 
(shMEX3A) compared to the control cells (shCTR) (Figure 6A–D). 
  
Figure 6. MEX3A impinges the proliferation of human A-172 and T98G GB cells. (A and I) A-172 (A) 
and T98G (I) cells were counted by trypan blue at the indicated time points to evaluate the growth 
rate after infection with lentiviral particles encoding either control shRNA (shCTR) or MEX3A 
shRNAs (shMEX3A#1 and shMEX3A#2). (B and J) Infected A-172 (B) and T98G (J) cells were seeded 
in 96-well tissue culture plates, and their proliferation was measured as cell confluence (%) calculated 
using IncuCyte Zoom software by phase-contrast images. Cells were scanned every two hours from 
0 to 72 h after infection. The graph shows data ± SD analyzed by using the IncuCyte software (Essen 
BioScience). (C and K) The graphs show the percentage of BrdU uptake in A-172 (C) and T98G (K) 
transduced with lentiviral particles encoding either control shRNA (shCTR) or MEX3A shRNAs 
(shMEX3A#1 and shMEX3A#2). (D and L) Representative immunofluorescence images of the BrdU 
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incorporation shown in (C) and (K), respectively. Scale bar: 5 μm. (E,F and M,N) Immunoblot and 
densitometric analysis of cleaved PARP protein in A-172 (E,F) and T98G (M,N) cells transduced with 
lentiviral vector encoding either control shRNA (shCTR) or MEX3A shRNA#2. (G and O) Infected A-
172 (G) and T98G (O) cells were seeded in 96-well tissue culture plates and cultured for 36 h, to reach 
100% confluence. Then, cells were scratched, and images of wounds were automatically acquired 
within the CO2 incubator by IncuCyte zoom software. The wound image updates were taken at 2 h 
intervals for the duration of the experiment. The graph shows data ± SD analyzed with respect to 
wound confluence and calculated by using the IncuCyte software package. (H and P) Representative 
images of the data are shown in (G) and (O), respectively. All data represent the mean of three 
independent experiments. Mean ± SD; * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001 calculated with 
two-sided Student’s t-test. 
This was consistent with increased levels of the cleaved PARP protein (Figure 6E,F). Of note, 
also the migration ability of A-172 cells was significantly impaired following genetic depletion of 
MEX3A (Figure 6G,H). Importantly, similar results were observed in A-172 cells treated with cell 
cycle thymidine, demonstrating that this effect was independent of the decrease in cell proliferation 
due to MEX3A gene silencing (Supplementary Figure S3A–D). These data were confirmed also in 
T98G cell line (Figure 6I–P and Supplementary Figure S3E–H). 
These data suggest the inhibition of MEX3A as a potential therapeutic approach for the 
treatment of GB. 
3. Discussion 
GB is the most common malignant primary brain tumor, driven by complex signaling pathways 
and particularly difficult to treat [4,35]. Although the current therapeutic protocols have been refined, 
GB remains a fatal human cancer, in which the estimated survival is 8 to 15 months [2,35]. 
Chemotherapy with Temozolomide (TMZ), the most used drug in GB treatment, shows acquired 
resistance caused by the high levels of activity of DNA repair enzyme O6-methylguanine DNA 
methyltransferase (MGMT) in tumor cells that reduces the effect of this alkylating agent. 
Unfortunately, other mechanisms contribute to the resistance to TMZ, such as overexpression of 
epidermal growth factor receptor (EGFR), galectin-1, MDM2, p53 and PTEN mutations [36]. 
Moreover, the significant heterogeneity of this tumor represents a potential source of therapeutic 
resistance and one of the main hindrances in the identification of new pharmacological targets for the 
development of more effective drugs. Furthermore, recent studies highlighted a complex crosstalk 
between tumor cells and the microenvironment, especially enhanced angiogenesis and aberration in 
anticancer immune response, which could be the cause of more aggressive tumor phenotype and 
failure of treatments effectiveness [2,5]. All of these issues represent a dramatic challenge for the 
development of new therapies and raise the need to improve the knowledge of the molecular 
mechanisms underlying GB tumorigenesis. 
At present, it is clearly demonstrated that post-translational modifications play a crucial role in 
the control of normal cellular processes, but also in cancer initiation and progression [37–40].  
Here, we described for the first time that the RNA-binding MEX3A affects GB proliferation, 
acting as an E3-ubiquitin ligase. So far, little is known about the role of this protein in carcinogenesis 
[21–24,26]. Although MEX3A is a member of the RNA-binding ubiquitin ligase MEX3 protein family, 
its function as E3-ligase and its potential substrates have not yet been described. 
We found that MEX3A is strongly up-regulated in GB specimens compared to the normal brain 
tissues and regulates the protein stability of RIG-I. The multifunctional protein RIG-I is an important 
PRR involved in the activation of antiviral innate immunity and interferon response pathway [29], 
and known to play many other biological roles. Interestingly, recent studies have described that RIG-
I activation by RNA ligands is essential in the induction of cell growth arrest via apoptosis and 
immune activation in several types of cancers, including GB [32,33,41].  
In particular, Glas and colleagues [32,33,41] suggested that the activation of the innate immune 
system could occur by stimulation of innate immune receptors involved in antiviral and antitumor 
responses, such as RIG-I and MDA5. More intriguingly, they showed that the increased expression 
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levels of RIG-I and MDA5 by interferon stimulation could mediate immune response and allow 
hitting different GB malignant cells, including cancer stem cells, with low level of neurotoxicity. 
Targeting the cytosolic innate immune receptors in GB stands as innovative strategy to overcome 
therapeutic resistance due to cellular heterogeneity and immune escape mechanisms [42,43]. 
RIG-I activity is significantly modulated through ubiquitylation processes mediated by several 
E3 ligases [34,44–47], differentially expressed depending on the tumor context [48,49]. MEX3C, 
TRIM4 and TRIM25 are the most important E3 ligases for positive regulation of RIG-I activity in 
response to viral infection, whereas RNF122 and RNF125 have been described to mediate the 
ubiquitin-dependent degradation of this cytosolic innate immune receptor.  
In our study, we found higher expression levels of MEX3A and RNF122, compared to other E3 
ligases, and lower baseline protein levels of RIG-I in GB specimens than in paratumor tissues. This 
evidence suggests the prevalence of degradative rather than regulative processes on the control of 
RIG-I in GB. 
We demonstrated that MEX3A interacts with ubiquitylates RIG-I, promoting its proteasome-
dependent degradation and altering its stability. We showed that the gene silencing of MEX3A 
increases protein levels of RIG-I and strongly inhibits the proliferation of human GB cells (Figure 7). 
 
Figure 7. A representative model showing the role of MEX3A and RIG-I in GB tumorigenesis. RNA-
binding ubiquitin ligase MEX3A ubiquitylates and induces the proteasome degradation of RIG-I, thus 
favoring GB growth. On the other hand, genetic depletion of MEX3A results in the increase of RIG-I 
protein levels impairing GB proliferation. The inhibition of MEX3A and/or the activation of RIG-I 
could represent promising multi-targeting strategies for GB treatment. 
In this scenario, the stimulation of RIG-I, as well as the design of MEX3A inhibitors or small 
molecules able to counteract the binding between MEX3A and RIG-I might represent a novel strategy 
for cancer immunotherapy, by improving the dual function of RIG-I as cell death inducer and 
immune response activator (Figure 7). Targeting RIG-I and MEX3A could open innovative 
perspectives for new multi-targeting approaches in the treatment of GB. 
4. Material and Methods 
4.1. Cell Cultures, Transfections and Lentiviral Infections 
HEK293T (cod. CTR-3216TM) and human glioblastoma A-172 cells (purchased from the American 
Type Culture Condition, ATCC) were cultured in Dulbecco’s Modified Eagle Medium (DMEM, 
Sigma Aldrich (St. Louis, MO, USA) supplemented with 10% fetal bovine serum (FBS; Sigma-
Aldrich). Human glioblastoma multiforme T98G and human glioblastoma-astrocytoma U-87, 
(purchased from ATCC) cells were maintained in Eagle’s minimum essential medium (MEM, Sigma 
Aldrich plus 10% FBS. All media contained 1% Penicillin–Streptomycin and 1% Glutamine 
(Invitrogen, Gaithersburg, MD, USA). 
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GB, paratumoral biopsies and their related information were obtained under written informed 
consent and ethical approved by the Internal Review Board of the Umberto I, Policlinico of Rome 
(#3623). Mycoplasma contamination in cell cultures was routinely monitored by using a PCR 
detection kit (Applied Biological Materials, Richmond, BC, Canada). 
Transient transfections were performed by using DreamFectTM Gold transfection reagent (Oz 
Biosciences SAS, Marseille, France) in accordance with the manufacturer’s protocol.  
Lentiviral particles were generated in HEK293 cells transfected with packaging and envelope 
plasmids (pCMV-dR8.74 and VSV-G/pMDG2), pGFP-pLKO.1 plasmids (shCTR TR30021; shMEX3A 
TL308061B (#1), TL308061C (#2), Origene, Rockville, MD, USA). A-172 and T98G cells were infected 
with complete medium of HEK293 cells containing lentiviral particles and polybrene (8μg/mL, 
Sigma-Aldrich) for 72 h. 
4.2. Plasmids, Antibodies and Treatments 
The pCMV6-Entry-Myc-DDK-RNF122 (RC210868), pCMV6-Entry-Myc-DDK-MEX3A 
(RC215359), pCMV6-Entry-Myc-DDK-MEX3C (RC221125),pCMV6-AC-GFP-DDX58 (RG217615), 
non-effective Scrambled shRNA Cassette in pGFP-C-shLenti Vector (shCTR, TR30021), pGFP-C-
shLenti-MEX3A (TL308061B (#1) and TL308061C (#2)) were purchased from Origene (Rockville, MD, 
USA). 
Mouse anti-RIG-I D-12 (sc-376845, 1:1000 for WB, 1:100 for IHC), anti-RIG-I HRP conjugated D-
12 (sc-376845, 1:2000), mouse anti-HA-probe F-7 HRP (sc-7392 HRP, 1:1000) and mouse anti-β-Actin 
C4 (sc-47778, 1:2000) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Anti-
Flag M2 HRP (A8592, 1:1000) was purchased from Sigma-Aldrich. Rabbit anti-RIG-I (D14G6, 1:1000) 
and Rabbit anti-PARP (95426S) were purchased from Cell Signaling (Beverly, MA, USA). Rabbit anti-
MEX3A (ab79046, 1:1000 for WB, 1:100 for IHC) was purchased from Abcam (Cambridge, UK). HRP-
conjugated secondary antibodies were purchased from Bethyl Laboratories (Montgomery, TX, USA). 
Where indicated, cells were treated with MG132 (50 μM; Calbiochem, Nottingham, UK) for 4 h, 
Cycloheximide (100 μM, Sigma Aldrich) at indicated time. 
4.3. Immunoblot Analysis and Immunoprecipitation 
For Immunoblot analysis, cells were lysed in a solution containing RIPA buffer (50 mM Tris-HCl 
at pH 7.6, 150 mM NaCl, 0.5% sodium deoxycholic, 5 mM EDTA, 0.1% SDS, 100 mM NaF, 2 mM 
NaPPi and 1% NP-40) supplemented with protease and phosphatase inhibitors. The lysates were 
incubated on ice and then centrifuged at 13,000 g for 30 min, at 4 °C. After centrifugation, a 
determined amount of supernatant was resuspended in sample loading buffer, boiled for 5 min, 
resolved in SDS-PAGE and then subjected to immunoblot analysis. For Co-immunoprecipitation (Co-
IP) assays, cell pellets were lysed with Triton Buffer (50 mM Tris-HCl pH 7.5, 250 mM sodium 
chloride, 50 mM sodium fluoride, 1 mM EDTA pH 8 and 0.1% Triton X-100), supplemented with 
protease and phosphatase inhibitors. An established amount of the whole-cell protein extracts was 
immunoprecipitated overnight at 4 °C, with rotation with specific primary antibodies (2 μg/mg of 
protein lysate) or IgG used as a control (2 μg/mg of protein lysate; Santa Cruz Biotechnology) and 
then incubated with Protein agarose beads (Santa Cruz Biotechnology) for 1 h, at 4 °C, with rotation. 
The immunoprecipitates were then washed five times with the lysis buffer described above, 
resuspended in sample loading buffer, boiled for 5 min, resolved in SDS-PAGE and then subjected to 
immunoblot analysis. 
Clinical samples for immunoblot analysis or Co-IP assay were mechanically disrupted in RIPA 
buffer or Triton buffer, respectively, supplemented with protease and phosphatase inhibitors. The 
lysates were sonicated for 10′’ at 100 W amplitude in ice and then centrifuged at 13,000 g for 30 min 
at 4 °C. The lysates were assayed with the procedures described above. 
4.4. In Vivo Ubiquitylation Assay 
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HEK293T were transfected with equal amount of GFP-RIG-I and HA-Ub and with Myc-MEX3A 
in 1:20, 1:10 and 1:5 ratio compared to GFP-RIG-I amount. After 24 h from transfection, cells were 
treated with MG132 (50 μM) or DMSO as control, for 4 h. Cells were lysed in a solution containing 
RIPA buffer, as described above. Lysates were subjected to immunoprecipitation with mouse anti-
RIG-I (Santa Cruz Biotechnology), overnight, at 4 °C, with rotation. The immunoprecipitated proteins 
were then washed five times with the RIPA lysis buffer, resuspended in sample loading buffer, boiled 
for 5 min, resolved in SDS-PAGE and then subjected to immunoblot analysis. Polyubiquitylated 
forms were detected by using mouse anti-HA from Santa Cruz Biotechnology. 
4.5. Cell Proliferation Assay 
Trypan blue count was performed in GB cell lines, silenced by infection with lentiviral particles 
encoding either control shRNA (shCTR) or MEX3A shRNAs (shMEX3A#1 and shMEX3A#2) to assess 
the growth rate and cell viability. BrdU incorporation assay (Roche, Welwyn Garden City, UK) was 
used to determine cell proliferation in A-172 and T98G cells. First, cells were infected with lentiviral 
particles encoding either short hairpin RNA targeting human MEX3A or a control non-targeting 
sequence (shCTR) for 72 h, pulsed 24 h with BrdU and then fixed and permeabilized with 4% 
paraformaldehyde and 0.2% Triton X-100 (Sigma Aldrich). Dako Fluorescent mounting (Dako, 
Carpinteria, CA, USA) was used as mounting medium, and nuclei were counterstained with Hoechst 
reagent; BrdU detection was performed according to the manufacturer’s instructions. At least 500 
nuclei were counted in triplicate, and the number of BrdU-positive nuclei was recorded. 
For IncuCyte® S3 experiments, infected A-172 and T98G cells were seeded in 96-well plates (20 × 
103 cells/well for both cell lines; 12 wells for each condition) in complete medium and incubated 
overnight. The day after seeding, T98G cells were treated with IncuCyte® NucLight Rapid Red 
Reagent (#4717, Essen BioScience, 1:1000). Plates were transferred into the IncuCyte® S3 Live Cell 
Analysis Systems and incubated at physiological condition (37 °C, 5% CO2), over 72 h. Images were 
collected every 2 h, and proliferation was evaluated as number of NucLight positive cells for T98G, 
or as cell confluence for A-172, which does not incorporate NucLight reagent. The experiments were 
performed in triplicate, and data were analyzed by using the IncuCyte software package (Essen 
BioScience, Ann Arbor, MI, USA). 
4.6. mRNA Expression Analysis 
Total RNA was isolated from GB and paratumoral biopsies, using TRIzol reagent 
(Invitrogen/Life Technologies, Carlsbad, CA, USA), and reverse-transcribed with a SensiFAST cDNA 
Synthesis Kit (Bioline Reagents Limited, London, UK). Quantitative real-time PCR (qRT-PCR) 
analysis of MEX3A, RNF122, MEX3C and RIG-I mRNA expression was performed by using the 
ViiATM 7 Real-Time PCR System (Life Technologies). Standard qPCR thermal cycler parameters were 
used to amplify a reaction mixture containing cDNA template, SensiFAST SYBR Lo-ROX Kit (Bioline 
Reagents Limited, London, UK) and primer probe. Then, mRNA quantification was performed by 
using SDS version 2.3 software, each sample was amplified in triplicate, and the average of the three 
threshold cycles was used to calculate the number of transcripts. Data were normalized with the 
endogenous housekeeping genes (GAPDH and HPRT) and expressed as the fold change respect to 
the control sample value. 
The following primers were used to amplify the indicated genes: 
hMEX3A For 5′- ATCGTGGGCAGG CAAGGCT-3′ 
hMEX3A Rev 5′- GCTGCTGAGATGATTT CCC-3′  
hRNF122 For 5′- CCAACAAGTCCTGCTCGATG-3′ 
hRNF122 Rev 5′- ACTGCGCAGGTCTGCCCATA-3′ 
hMEX3C For 5′ –TGAACGGGGAGCAGGCG-3′ 
hMEX3C Rev 5′- TGACTTGGACGGTGGTTTGA-3′ 
hRIG-I For 5′- TGTGCTCCTACAGGTTGTGGA-3G 
hRIG-I Rev 5I- CACTGGGATCTGATTCGCAAA A-3n 
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hGAPDH For 5′- TCCCATCACCATCTTCCAGG-3′ 
hGAPDH Rev 5′- ATGAGTCCTTCCACGATACC-3′ 
hHPRT For 5′- ATTATGCTGAGGATTTGGAAAGGG-3′ 
hHPRT Rev 5′- GCCTCCCATCTCCTTCATCAC-3′ 
4.7. Immunohistochemistry 
Tissues used for immunohistochemical staining were fixed in formalin and paraffin-embedded 
(FFPE). FFPE slides were incubated with monoclonal antibodies against RIG-I or MEX3A (1:100, 
overnight, at 4 °C). The day after, the slides were incubated for 20 min, with secondary antibodies 
coupled with peroxidase (Dako). Bound peroxidase was detected by diaminobenzidine (DAB) 
solution (ScyTek Laboratories, Logan, UT, USA) and EnVision FLEX Substrate buffer containing 
peroxide (Dako). Cell quantification was performed on collected sections, using the imaging software 
NIS-Elements BR 4.00.05 (Nikon Instruments Europe B.V., Florence, Italy). Images were captured by 
HistoFAXS software (TissueGnostics GmbH, Vienna, Austria), at 20× magnification. 
4.8. In Vitro Wound Healing Assay 
A-172 and T98G cells were infected with lentiviral particles encoding short hairpin RNA 
targeting MEX3A (shMEX3A) or a control non-targeting sequence (shCTR). Then, 20 × 103 cells/well 
were seeded into a 96-well ImageLock tissue culture plate (Essen BioScience; 12 wells for each 
condition) and incubated at 37 °C with 5% CO2 incubator, for 36 h, until they reached 100% 
confluence. Wounds were made by the 96-well WoundMaker (Essen BioScience). The wounded cells 
were washed twice to remove the detached cells, and then incubated at 37 °C, in complete medium, 
with or without Thymidine 5 mg/mL (89270-5G, Sigma-Aldrich), to block the proliferation. Images 
of the wounds were automatically acquired within the incubator by IncuCyte zoom software (Essen 
BioScience). The wound image updates were taken at 2 h intervals for the duration of the experiment. 
Data were analyzed with respect to wound confluence and calculated by using the IncuCyte software 
package (Essen BioScience). 
4.9. Statistical Analysis 
Statistical analysis was performed by using the StatView 4.1 software (Abacus Concepts, 
Berkeley, CA, USA). For all experiments, p-values were determined by two-tailed Student’s t-test, 
and statistical significance was set at p < 0.05. Results are expressed as mean ± SD from an appropriate 
number of experiments (at least three biological replicas). 
5. Conclusion 
In this work, we identified new molecular players involved in GB tumorigenesis. The RNA-
binding ubiquitin ligase MEX3A was found up-regulated in GB specimens, and this correlates with 
low protein levels of the tumor-suppressor RIG-I. We showed that MEX3A binds and ubiquitylates 
RIG-I, inducing its proteasome degradation. Genetic depletion of MEX3A results in the increase of 
RIG-I protein levels and the inhibition of GB cell growth. Our study unveils a new molecular 
mechanism involved in GB tumorigenesis and suggests that targeting RIG-I and MEX3A could pave 
the road for new therapeutic strategies for GB. 
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gene expression profile in normal brain tissues and different GB datasets from R2 Genomics Analysis and 
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figures. Table S1: Gene expression level of the significantly modulated catalytic E3 ubiquitin ligases and F-box 
proteins in GB compared to normal brain tissues from GEPIA, Table S2, Specific characteristics of individual 
patient specimens.  
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